Pig-derived exosomes as Alzheimer’s therapy: systemic barriers to biotech innovation and ethical oversight
Original framing: “China’s ‘pig semen eyedrop’ may help treat Alzheimer’s: scientist in Australia” — South China Morning Post
The pig semen eyedrop narrative embodies the trickster’s role in exposing the absurdity of sensationalized biotech claims, inverting the solemnity of scientific progress to reveal its ethical and practical flaws. By framing a highly unconventional therapy as a potential breakthrough, the story disrupts conventional wisdom and challenges the uncritical celebration of innovation. This inversion clarifies the systemic barriers obscured by mainstream narratives, such as regulatory gaps and the commodification of life.
The narrative of 'pig semen eyedrops' for Alzheimer’s exemplifies the tension between sensationalized biotech innovation and systemic inequities in global health.
While exosomes hold promise as drug delivery vehicles, their development is shaped by geopolitical power dynamics, ethical blind spots, and the historical legacy of exploitative biomedical research. The focus on a single breakthrough obscures the need for interdisciplinary collaboration, equitable benefit-sharing, and culturally grounded approaches to neurodegenerative diseases. Indigenous and traditional knowledge systems offer holistic frameworks that could complement Western biomedical research, but their integration is hindered by regulatory, cultural, and economic barriers. Ultimately, addressing Alzheimer’s requires moving beyond isolated technological fixes to address the structural determinants of health, including environmental degradation, socioeconomic disparities, and the commodification of life itself.